We are excited to welcome you to our webinar on Polycystic Ovarian Disease (PCOD), scheduled for June 19, 2025. This session will feature expert insights on the causes, diagnosis, and management of PCOD, offering valuable takeaways for healthcare professionals, researchers, and individuals seeking a deeper understanding of this condition.
This webinar is designed to provide valuable knowledge, expert insights, and practical solutions for managing PCOD effectively. With leading healthcare professionals and specialists sharing their expertise, we aim to create awareness, debunk myths, and empower individuals with the right information.
Join us for an insightful PCOD Webinar designed to spread awareness and provide expert guidance on Polycystic Ovarian Disease (PCOD). This virtual event will bring together leading healthcare professionals, researchers, and wellness experts to discuss the latest developments in PCOD diagnosis, treatment, and holistic management.
This webinar is designed to provide in-depth knowledge and expert insights on Polycystic Ovarian Disease (PCOD), covering various aspects of diagnosis, treatment, lifestyle, and mental well-being.
The global market for treating polycystic ovarian syndrome was valued at USD 4.53 billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 6.5% between 2024 and 2030. This growth is largely due to changes in lifestyle, increased alcohol consumption, rising levels of anxiety and depression, and hormonal imbalances. According to data released by the World Health Organization (WHO) in June 2023, PCOS affects 8-13% of women of reproductive age, with approximately 70% of those affected remaining undiagnosed worldwide.
The incidence of diabetes is increasing among individuals with polycystic ovarian syndrome. The World Health Organization (WHO) indicates that women who have a family history of type 2 diabetes are more susceptible to developing polycystic ovarian syndrome. Furthermore, the Centers for Disease Control and Prevention (CDC) has reported that individuals with this condition cannot produce insulin, a crucial hormone for regulating blood sugar, which leads to insulin resistance and the development of type 2 diabetes. The rise in such chronic conditions is anticipated to propel the growth of the treatment market.
Obesity also plays a significant role in the development of polycystic ovarian syndrome. The World Health Organization (WHO) reported that in 2022, 2.5 billion adults were classified as overweight, with women making up 44% of this population. Many individuals suffering from this syndrome also experience obesity, and the progression of weight gain is linked to the worsening of PCOS, as per endocrine experts. The increase in these health issues, along with the growing number of polycystic ovarian syndrome cases, is contributing to market expansion.